Shots:

• The US FDA has approved the Chemistry- Manufacturing and Controls (CMC) Prior-Approval Supplement (PAS) for the Eylea (2mg- single dose) sterilized prefilled syringe with its expected availability to the physicians and patients in H2’19
• The sterilized prefilled syringe offers the same medication as the currently available Eylea providing ease of administration and is available in multiple dosing intervals- offering doctors the flexibility to address patient’s needs
• Eylea is a VEGF inhibitor targeting VEGF-A and PLGF- formulated as an injection for the eye- act by blocking the growth of new blood vessels and by decreasing vascular permeability in the eye and is approved therapy for Wet AMD- macular edema following RVO- DME and DR in the US  

Click here to­ read full press release/ article | Ref: Regeneron | Image: Wsca